Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMINOPHYLLINE vs ELIXOPHYLLIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aminophylline is a bronchodilator and respiratory stimulator that acts as a non-selective phosphodiesterase inhibitor, increasing cyclic AMP levels, and as an adenosine receptor antagonist. It also enhances diaphragmatic contractility and mucociliary clearance.
Inhibits phosphodiesterase, increasing intracellular c AMP, leading to bronchodilation and anti-inflammatory effects.
Treatment of acute bronchospasm in asthma and COPD,Treatment of apnea of prematurity,Off-label: adjunctive therapy in COPD exacerbations, status asthmaticus
Treatment of asthma,Treatment of chronic obstructive pulmonary disease (COPD),Apnea of prematurity (off-label)
Loading dose: 5-6 mg/kg IV over 20-30 minutes (if no recent theophylline). Maintenance: 0.4-0.6 mg/kg/hour IV continuous infusion; oral: 300-600 mg/day divided every 6-8 hours.
Theophylline (Elixophyllin) immediate-release: Initial dose 300 mg/day PO divided every 6-8 hours; titrate based on serum theophylline concentration (target 5-15 mcg/m L). Typical adult dose 400-600 mg/day PO divided every 6-8 hours. Sustained-release: 400-600 mg/day PO every 12 hours.
Adults: 7-9 hours (nonsmokers), 4-5 hours (smokers), 10-20 hours (neonates, hepatic impairment, CHF).
Terminal elimination half-life in adults is approximately 7-9 hours (range 3-12 hours) for non-smokers, and 4-5 hours for smokers. In children (1-9 years), half-life averages 3-4 hours; in neonates, it is prolonged (20-30 hours). Clinical context: Half-life may be increased in hepatic impairment, congestive heart failure, and with concurrent administration of drugs that inhibit CYP1A2 and CYP3A4 (e.g., cimetidine, erythromycin, ciprofloxacin). Decreased half-life occurs with enzyme inducers (e.g., phenytoin, carbamazepine, rifampin, smoking).
Hepatic metabolism via CYP1A2 and xanthine oxidase; demethylation and oxidation yield active metabolites (caffeine and 3-methylxanthine).
Primarily hepatic via cytochrome P450 enzymes, mainly CYP1A2 and CYP3A4.
Renal: ~10% unchanged; hepatic metabolism (N-demethylation, oxidation) accounts for >80% of elimination; <1% fecal.
Theophylline is primarily eliminated by hepatic metabolism (approximately 90%), with less than 10% excreted unchanged in urine. Renal excretion of unchanged drug accounts for about 10% in adults, but in neonates and infants, it may be higher (up to 50%). Fecal excretion is negligible (<1%).
Approximately 40-60% bound to albumin in adults; lower in neonates (20-30%) and patients with hepatic disease.
Approximately 40-60% bound to plasma proteins, primarily albumin. Binding is saturable and may decrease in uremia or with elevated bilirubin. In neonates, protein binding is lower (about 20-30%) due to decreased albumin concentrations.
0.3-0.7 L/kg (average 0.45 L/kg); increased in neonates, cirrhosis, and CHF.
Volume of distribution: approximately 0.45 L/kg (range 0.3-0.7 L/kg). Clinical meaning: Theophylline distributes into total body water, with some accumulation in tissues. Vd is increased in neonates (0.6-0.9 L/kg) and decreased in obesity (0.3-0.4 L/kg adjusted for ideal body weight).
Oral: ~100% (well-absorbed); Rectal: ~80-100% (variable); IM: ~100% (avoid due to pain and unpredictable absorption).
Oral immediate-release: 90-100% (well absorbed). Oral extended-release: 80-100% (inter- and intra-subject variability exists). Rectal solution: 80-90%. Rectal suppository: 60-70% (erratic absorption). Intravenous: 100%.
No specific dose adjustment required based on GFR; monitor theophylline levels closely in renal impairment.
Theophylline pharmacokinetics are not significantly altered in renal impairment. No dose adjustment recommended for GFR >15 m L/min. For end-stage renal disease (GFR <15 m L/min), monitor serum theophylline concentrations closely as clearance may be reduced; consider 25% dose reduction and follow levels.
Child-Pugh A: reduce dose by 25%; Child-Pugh B: reduce dose by 50%; Child-Pugh C: reduce dose by 50-75% or consider alternative.
Child-Pugh Class A: Reduce dose by 50% of usual. Child-Pugh Class B: Reduce dose by 50-75% of usual. Child-Pugh Class C: Contraindicated or reduce dose by 80% with close monitoring. Serum theophylline concentration monitoring is mandatory.
Oral: 5 mg/kg/dose every 6 hours; IV loading: 5-6 mg/kg; maintenance: 0.5-0.9 mg/kg/hour for ages 6 months-9 years, 0.4-0.5 mg/kg/hour for ages 9-16 years.
Immediate-release: Initial dose 16 mg/kg/day or 400 mg/day (whichever is less) PO divided every 6-8 hours; titrate based on serum theophylline concentration. Typical maintenance: <1 year: 0.2 x age in weeks + 5 mg/kg/day; 1-9 years: 24 mg/kg/day; >9 years: 16 mg/kg/day. Maximum dose 800 mg/day.
Reduce initial dose by 50% (e.g., 0.2-0.3 mg/kg/hour IV) due to decreased clearance; monitor serum theophylline levels and titrate slowly.
Elderly patients (>60 years) have reduced theophylline clearance. Initial dose 300 mg/day PO divided every 8-12 hours; maximum recommended dose 400 mg/day. Monitor serum theophylline concentrations closely and adjust to avoid levels >15 mcg/m L due to increased risk of toxicity.
No FDA boxed warning exists; however, use caution in patients with acute myocardial injury due to potential arrhythmias.
No FDA black box warning.
Narrow therapeutic index requiring monitoring of serum theophylline levels; increased seizure risk at high concentrations; arrhythmia risk; caution in heart failure, hepatic impairment, and elderly.
Monitor serum theophylline levels due to narrow therapeutic index; risk of toxicity with levels >20 mcg/m L. Use caution in patients with cardiac disorders, hepatic impairment, elderly, and those on medications that alter theophylline metabolism.
Hypersensitivity to aminophylline, theophylline, ethylenediamine; uncontrolled arrhythmias; active seizure disorder; peptic ulcer; severe hypertension.
Hypersensitivity to theophylline or any component of the formulation; peptic ulcer disease; seizure disorder (unless adequately controlled).
Avoid high-fat meals which can decrease absorption and lead to variable serum levels. Limit caffeine intake (coffee, tea, cola, chocolate) as it may increase theophylline toxicity and side effects. Charcoal-broiled foods and a high-protein, low-carbohydrate diet may increase clearance of theophylline. Consistently maintain dietary habits to avoid fluctuations in theophylline levels.
Avoid high-caffeine foods and beverages (coffee, tea, cola, chocolate) as they may potentiate stimulant effects and increase risk of toxicity. Dietary protein and charcoal-broiled meats may increase clearance, potentially reducing efficacy. Consistency in diet is recommended.
Aminophylline is a bronchodilator containing theophylline and ethylenediamine. Theophylline crosses the placenta and fetal serum concentrations approximate maternal levels. In the first trimester, limited data do not indicate a significant increase in major malformations, but the drug should be used only if clearly needed. In the second and third trimesters, theophylline may cause fetal tachycardia, jitteriness, and irritability if maternal levels are high. Near term, accumulation of theophylline in the fetus may lead to neonatal withdrawal (irritability, apnea) and transient tachycardia. Risk is dose-dependent and more pronounced at serum levels >15 mcg/m L.
Pregnancy Category C. First trimester: Studies in animals have shown an increased risk of fetal malformations (e.g., cardiac defects, cleft palate) at high doses. Human data limited; may be associated with intrauterine growth restriction and neonatal withdrawal if used near term. Second trimester: Risk of tachyarrhythmias and fetal hypoxia due to maternal toxicity. Third trimester: Increased risk of neonatal apnea, jitteriness, and irritability due to transplacental passage. Avoid use unless clearly needed.
Theophylline is excreted into breast milk with a milk-to-plasma (M/P) ratio of approximately 0.7. Infant exposure is estimated to be 1–10% of the maternal weight-adjusted dose. Premature infants or those with impaired clearance are at risk for accumulation and toxicity (irritability, jitteriness, feeding intolerance). Breastfeeding is generally considered acceptable if maternal serum levels are within therapeutic range (5-15 mcg/m L) and the infant is monitored for signs of theophylline toxicity. American Academy of Pediatrics classifies theophylline as compatible with breastfeeding, but caution is advised.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.7. Peak milk levels occur 2-4 hours after dose. Infant serum levels are typically low (10-30% of maternal levels). Risk of irritability and jitteriness in infants. Use with caution; monitor infant for adverse effects.
Pregnancy increases the clearance of theophylline by approximately 20-30% due to increased volume of distribution and hepatic metabolism (especially in the second and third trimesters). Doses may need to be increased by 20-30% to maintain therapeutic serum levels. Frequent monitoring of serum theophylline levels (every 1-2 weeks) is recommended to guide dose adjustments. Postpartum, clearance returns to prepregnancy levels within 2-3 months, so doses should be reduced to avoid toxicity.
Due to increased clearance of theophylline in pregnancy (by up to 30-50%), dose adjustments are often required. The half-life may decrease significantly, especially in the second and third trimesters. Consider starting with higher doses or more frequent intervals (e.g., every 6-8 hours). Monitor serum concentrations every 2-4 weeks and adjust to maintain therapeutic levels. Postpartum, clearance may decrease, requiring dose reduction.
1. Aminophylline is a bronchodilator that is a combination of theophylline and ethylenediamine; the ethylenediamine component may cause allergic reactions in sensitive individuals. 2. Monitor serum theophylline levels closely (therapeutic range: 10-20 mcg/m L); toxicity can occur at levels >20 mcg/m L with symptoms including nausea, vomiting, tachycardia, and seizures. 3. Use with caution in patients with severe hypoxemia, and treat with diltiazem or benzodiazepines for seizures if they occur. 4. Aminophylline can cause significant drug interactions, particularly with cimetidine, fluoroquinolones, and macrolide antibiotics which increase theophylline levels. 5. In acute asthma exacerbations, aminophylline is typically reserved for cases not responding to inhaled beta-agonists and corticosteroids due to narrow therapeutic index.
ELIXOPHYLLIN is a brand name for theophylline elixir. Monitor serum theophylline levels (therapeutic range 10-20 mcg/m L). Levels >20 mcg/m L increase toxicity risk. Use with caution in patients with hepatic impairment, heart failure, or COPD. Adjust dose based on smoking status (smokers require higher doses). Drug interactions: cimetidine, ciprofloxacin, fluvoxamine increase levels; phenytoin, carbamazepine, rifampin decrease levels.
Take this medication exactly as prescribed; do not chew or crush extended-release tablets.,Avoid consuming large amounts of caffeine (coffee, tea, chocolate, cola) as it may increase side effects such as nervousness and palpitations.,Notify your doctor immediately if you experience nausea, vomiting, irregular heartbeats, or seizures.,Do not smoke or stop smoking without consulting your doctor, as smoking affects how this medication works.,Keep a record of peak flow readings as directed by your healthcare provider.
Take this medication exactly as prescribed; do not change dose without consulting your doctor.,Avoid caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, diarrhea, headache, insomnia, irritability, rapid heartbeat, or seizures.,Do not crush or chew extended-release tablets; take elixir with a measuring device for accurate dose.,Notify your doctor if you start or stop smoking, as tobacco use affects how this drug works.,Store at room temperature away from moisture and heat.
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMINOPHYLLINE vs ELIXOPHYLLIN, answered by our medical review team.
AMINOPHYLLINE is a Xanthine Bronchodilator that works by Aminophylline is a bronchodilator and respiratory stimulator that acts as a non-selective phosphodiesterase inhibitor, increasing cyclic AMP levels, and as an adenosine receptor antagonist. It also enhances diaphragmatic contractility and mucociliary clearance.. ELIXOPHYLLIN is a Xanthine Bronchodilator that works by Inhibits phosphodiesterase, increasing intracellular c AMP, leading to bronchodilation and anti-inflammatory effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMINOPHYLLINE and ELIXOPHYLLIN depend on the specific clinical indication. These are both Xanthine Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMINOPHYLLINE is: Loading dose: 5-6 mg/kg IV over 20-30 minutes (if no recent theophylline). Maintenance: 0.4-0.6 mg/kg/hour IV continuous infusion; oral: 300-600 mg/day divided every 6-8 hours.. The standard adult dose of ELIXOPHYLLIN is: Theophylline (Elixophyllin) immediate-release: Initial dose 300 mg/day PO divided every 6-8 hours; titrate based on serum theophylline concentration (target 5-15 mcg/m L). Typical adult dose 400-600 mg/day PO divided every 6-8 hours. Sustained-release: 400-600 mg/day PO every 12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMINOPHYLLINE and ELIXOPHYLLIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMINOPHYLLINE is classified as Category C. Aminophylline is a bronchodilator containing theophylline and ethylenediamine. Theophylline crosses the placenta and fetal serum concentrations approximate maternal levels. In the . ELIXOPHYLLIN is classified as Category C. Pregnancy Category C. First trimester: Studies in animals have shown an increased risk of fetal malformations (e.g., cardiac defects, cleft palate) at high doses. Human data limite. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.